NMDAR

(redirected from N-methyl-D-aspartate receptor)
Also found in: Dictionary, Medical.
AcronymDefinition
NMDARN-Methyl-D-Aspartate Receptor
References in periodicals archive ?
Evidence for direct protein kinase-C mediated modulation of N-methyl-D-aspartate receptor current.
Block and modulation of N-methyl-D-aspartate receptors by polyamines and protons: Role of amino acid residues in the transmembrane and pore-forming regions of NR1 and NR2 subunits.
N-Methyl-D-Aspartate receptor subunit NR2B is widely expressed throughout the rat diencephalon: an inmunohistochemical study.
N-methyl-D-aspartate receptor NR1 subunit gene (GRINI) in schizophrenia: TDT and case-control analyses.
Detection of the N-Methyl-D-Aspartate Receptor Subunit-1 (NMDAR-1) in the Hypothalamus of the Sheep by Western Blot Analysis.
The remaining chapters address such topics as age-associated memory impairment, cognition in Alzheimer's disease and related disorders, cognitive deficits as a core feature of schizophrenia, cognition in depression and mania, linking pre-clinical and clinical approaches to therapy for cognitive dysfunction in neuropsychiatric and neurodegenerative disorders, modulation of n-methyl-d-aspartate receptor function as a novel approach for development of antipsychotic agents, mechanisms of plasticity in molecular and cellular cognition, and functional imaging of cognition related brain circuitry in health and schizophrenia.
Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
Ketamine, which directly targets the N-methyl-D-aspartate receptor complex, is known to produce adverse effects at higher doses or when used for a prolonged time, so it is unlikely to be used widely in clinical settings.
Glycine and calcium-dependent effects of lead on N-methyl-D-aspartate receptor function in rat hippocampal neurons.
N-methyl-D-aspartate receptor (NMDAR) antagonists are neuroprotective in animal models of stroke; however clinical trials have so far failed because of adverse central nervous system (CNS) effects induced by drugs targeting the NMDAR (Choi, 2002).
DXM acts on the same receptor as phencyclidine (PCP), the N-methyl-D-aspartate receptor.
Full browser ?